Skip to content
Screener

Shares (Diluted) at other companies

ALN
Alnylam PharmaceuticalsALNY
138.3M+5.9%
Intellia Therapeutics logo
Intellia TherapeuticsNTLA
133.5M+28.7%
CRISPR Therapeutics logo
CRISPR TherapeuticsCRSP
96.1M+11.8%
CytomX Therapeutics logo
CytomX TherapeuticsCTMX
218.9M+69.6%
Taysha Gene Therapies, Inc. logo
Taysha Gene Therapies, Inc.TSHA
369M+23.8%
Vor Biopharma logo
Vor BiopharmaVOR
43M+589%

Other financials

Income statement

See full
Revenue-
Operating income-$19.7M+3.5%
Net income-$17.6M+0.4%
EPS (diluted)-$0.29+6.5%

Balance sheet

See full
Cash & equivalents$12.8M-6.6%
Total debt$2.7M+27.7%
Total equity$218.1M-4.3%
Total assets$230.4M-3.0%

Cash flow

See full
Operating cash flow-$16.4M+2.1%
CapEx--100%
Free cash flow-$16.4M+2.6%

Valuation

See full
Market cap$875.52M+219%
Enterprise value$865.48M+237%

Profitability

See full
Operating margin-3,685.8%
Net margin-3,663.7%

Returns & leverage

See full
Return on equity-31.3%+19.5pp
Debt / equity0.0×
Current ratio22.3×-6.1×

Where this comes from

Reported directly by Design Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding.

The source filing: Design Therapeutics, Inc.’s 10-Q, filed April 28, 2026.

Filed
Apr 28, 2026, 4:13 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001193125-26-187063
Line itemThree Months Ended March 31, 2026Three Months Ended March 31, 2025
Research and development (including related party amounts of $72 and $228, respectively)$14,379$15,377
General and administrative (including related party amounts of $85 and $134, respectively)5,3275,041
Total operating expenses19,70620,418
Loss from operations(19,706)(20,418)
Interest income2,0702,703
Net loss$(17,636)$(17,715)
Net loss per share, basic and diluted$(0.29)$(0.31)
Weighted-average shares of common stock outstanding, basic and diluted61,434,45756,757,827

Item 1. Financial Statements.

FAQ

What is Design Therapeutics, Inc.'s shares (diluted)?
Design Therapeutics, Inc. (DSGN) reported shares (diluted) of 61.4M in Q1 2026.
How has Design Therapeutics, Inc.'s shares (diluted) changed year-over-year?
Design Therapeutics, Inc.'s shares (diluted) increased by 8.2% year-over-year, from 56.8M to 61.4M.
What is the long-term trend for Design Therapeutics, Inc.'s shares (diluted)?
Over 4 years (2021 to 2025), Design Therapeutics, Inc.'s shares (diluted) has grown at a 7.0% compound annual growth rate (CAGR), from 173.8M to 227.9M.
What does shares (diluted) mean?
The weighted-average shares outstanding plus all potentially dilutive shares from stock options, RSUs, convertible securities, and warrants, using the treasury stock method.

Ask your AI about Design Therapeutics, Inc.'s shares (diluted).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude